We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,900
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
New Insights on Neuropathic Pain Mechanisms as a Source for Novel Therapeutical Strategies

Sabatino Maione, Enza Palazzo, Francesca Guida, Livio Luongo, Dario Siniscalco, Ida Marabese, Francesco Rossi and Vito de Novellis

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/55276

1. Introduction

Injuries affecting either the peripheral or the central nervous system (PNS, CNS) leads to neuropathic pain characterized by spontaneous pain and distortion or exaggeration of pain sensation. Peripheral nerve pathologies are considered generally easier to treat compared to those affecting the CNS, however peripheral neuropathies still remain a challenge to therapeutic treatment.

Animal models such as denervation/neuroma formation [1], chronic constriction injury (CCI) by loose ligatures around the sciatic nerve [2], partial tight ligation of the sciatic nerve trunk (partial sciatic nerve ligation, PNL) [3]; tight ligature of L5 and L6 spinal nerves (spinal nerve ligation, SNL) [4]; section of one or two components of the sciatic nerve (spared nerve injury, SNI) [5]; streptozocin induced diabetic neuropathy [6] and peripheral neuropathy induced by vincristine or by anti-retroviral nucleoside analogue AIDS therapy drugs [7, 8] have been designed to mimic different neuropathic syndromes and reproduce in laboratory neuropathic pain main symptoms. Indeed all the mentioned neuropathic pain models show increased responses to thermal or mechanical nociceptive stimulation (hyperalgesia), hypersensitivity to innocuous tactile or cold stimuli (allodynia) which lead to withdrawal behaviour.

2. Peripheral pathophysiology change mechanisms

A large body of studies has been accumulated during the last two decades to characterize and clarify mechanisms at the base of neuropathic pain development and maintenance. Peripheral
nerve injury causes axon and myelin sheath degradation associated with macrophage, neutrophil and T cell infiltrations [9, 10].

The release of proinflammatory cytokines (interleukins, tumor necrosis factor-α) and mediators (bradykinins and prostaglandins) and growth factors (nerve growth factor) leads to peripheral sensitization and hypersensitivity to innocuous and noxious stimuli [11, 12]. Bradykinins and prostaglandins potentiate, among other things, the activity of transient receptor potential vanilloid type 1 (TRPV1) channel, highly expressed on Aδ and C fibers, whose activity and expression is potentiated in neuropathic pain models [13-16]. Neuropathic pain causes also over-expression of voltage gated sodium channels and increases sodium currents leading to spontaneous discharges of Aδ and C fibers [17-19]. Peripheral sensitization is also associated with increased voltage gated Ca²⁺ channels [20, 21]. Increased intracellular Ca²⁺ elevates substance P (SP) and glutamate release thus exacerbating pain transmission.

3. Spinal pathophysiology change mechanisms

Beside the peripheral mechanisms which are responsible of the immediate damage-induced changes in pain transmission, several spinal cellular and molecular changes are involved in the development of the neuropathic pain symptoms, such as thermal and mechanical hyperalgesia and tactile allodynia. Although first being thought as a disease of purely neuronal nature, several pre-clinical studies indicate that the mechanisms at the basis of the development and maintenance of neuropathic pain involve substantial contributions from the non-neuronal cells of both the PNS and CNS [22]. After peripheral nerve injury, microglia in the normal conditions (usually defined “resting” microglia) in the spinal dorsal horn proliferate and change their phenotype to an “activated” state through a series of cellular and molecular changes.

Microglia shift their phenotype to the hypertrophic “activated” form following altered expression of several molecules including cell surface receptors, intracellular signalling molecules and diffusible factors. The activation process consists of distinct cellular functions aimed at repairing damaged neural cells and eliminating debris from the damaged area [23]. Damaged cells release chemo-attractant molecules that both increase the motility (i.e. chemokinesis) and stimulate the migration (i.e. chemotaxis) of microglia, the combination of which recruits the microglia much closer to the damaged cells [24]. It has been shown that microglia activation in the spinal cord can be promoted by sciatic nerve ligation [25], spinal nerve ligation [26], sciatic nerve inflammation [27], traumatic nerve transection [28] and autoimmune diseases such as autoimmune encephalomyelitis and neuritis (EAE, EAN) [29, 30].

Once microglia become activated, they can exert both proinflammatory or anti-inflammatory/neuroprotective functions depending on the combination of the stimulation of several receptors and the expression of specific genes [31]. Thus, the activation of microglia following a peripheral injury can be considered as an adaptation to tissue stress and malfunction [32] that contribute to the development and subsequent maintenance of chronic pain [33, 34].
Spinal microglia respond quickly to injury, up-regulating cell surface proteins and increasing synthesis and the release of inflammatory mediators, including cytokines and proteases that can sensitize neurons, thereby establishing positive feedback which helps to facilitate nociceptive signalling [35]. Accordingly, the inhibition of microglia targets can reduce hypersensitivity in neuropathic pain states.

The signals responsible for neuron-microglia and/or astrocyte communication are being extensively investigated since they may represent new targets for chronic pain management. The first candidates are substances released by activated nociceptive primary afferent fibers, such as glutamate and SP, which are capable to activate microglia [36, 37]. Glutamate activates microglia by stimulating NMDA receptors [37], although other mechanisms involving metabotropic glutamate receptors (mGluRs) cannot be ruled out since it has been shown that mGluRs are expressed on microglial cells [38, 39]. SP acts mostly by activating microglia neurokinin-1 (NK1) receptors. Many mechanisms have been proposed for neuron-microglia crosstalk. Among these, the fractalkine (FKN, CX3CL1), a member of CX3C class of chemokines and its receptor CX3CR1 have been extensively investigated [39]. FKN is constitutively expressed by spinal cord and sensory neurons in the dorsal root ganglia (DRGs) [40-42], while CX3CR1 is exclusively expressed by microglia cells and, after peripheral nerve injury it is largely up-regulated in activated microglia [41]. FKN produces nociceptive behaviour by activating CX3CR1 on microglia and p38 mitogen-activated protein kinase (MAPK)-mediated pathways [42, 43]. A pathway for the cleavage of FKN from the membrane of neurons, has been elegantly demonstrated [42]. Briefly, neuronal FKN is cleaved by Cathepsin S (CatS), a proteolitic enzyme which is synthesized and released by activated microglia. Despite the CX3CL1/CX3CR1 pathway represents a pro-nociceptive non adaptive process, seems to perform also a neuro-protective action in neurodegenerative diseases [44].

Another chemokine implicated in neuron-glia communication is the chemokine (C-C motif) ligand 2 (CCL2, MCP-1), which is de novo expressed by sensory neurons as early as a day after peripheral injury [44]. Once released, CCL2 activates microglia via interaction with CCR2 receptors, and, accordingly, mice lacking CCR2 receptors display a reduction in nerve injury-induced tactile allodynia [45]. The action of the monocyte chemoattractant protein 1 (MCP-1) at the spinal level has also been demonstrated by the intrathecal administration of an MCP-1 neutralizing antibody, which proved able to inhibit neuropathic pain symptoms [44]. Another important candidate for neuronal-microglial cross-talk is ATP, that is produced by neurons as well as by glial cells. ATP exerts its effect on microglia by activating the purinergic ionotropic P2X4 and P2X7, as well as the metabotropic P2Y6 and P2Y12, receptors which are up and/or down-regulated in several conditions [46]. The stimulation of the P2X4 channel seems to be involved in the development of neuropathic pain by inducing the release of brain derived neurotrophic factor (BDNF) [47, 48]. In particular, this mechanism is believed to be responsible of the appearance of the tactile allodynia by inverting the ionic gradient of the GABAergic interneurons following the down-regulation of the KKC2 calcium transporter [47]. P2X4 receptor activation occurs earlier than that of P2X7 channel due to the greater affinity of ATP to bind to P2X4 receptor. Indeed, P2X7 is involved in the maintenance of microglial activation. The P2X7 receptor appears to be a functionally unique ionotrophic receptor among the P2X
receptor family since its activation is able to stimulate the release of the pro-inflammatory cytokine interleukin-1β (IL-1β) [49], as well as a variety of other pro-inflammatory cytokines. Recent studies have revealed that P2Y12R is also crucial in neuropathic pain induction and maintenance. It has been found that the expression of P2Y12R mRNA and protein are markedly enhanced in the spinal cord ipsilaterally to spinal nerve injury [50] or to sciatic nerve partial ligation [51]. The cellular location of this receptor in the spinal cord was highly restricted to microglia and recently has been proposed to be involved in the motility of microglial cell bodies and processes [52]. It is therefore possible that P2Y12R activity in microglia affects their ability to extend the branched processes toward neighbouring neurons of the pain matrix, which, in turn, may interfere with microglia-neuron communications. Recent data suggest that the metabotropic adenosine receptor A2A is also involved in the microglia process retraction occurring during microglia activation [53]. The up-regulation of Gs-protein-coupled adenosine A2A receptor on activated microglia seems to occur concomitantly to down regulation of Gi-protein coupled P2Y12 receptor [53].

4. Supraspinal pathophysiology change mechanisms

Descending pain modulatory system undergoes morpho-functional changes following PNS or CNS injury contributing to neuropathic pain development and maintenance [54-56]. The pain modulatory centers include brainstem areas such as periaqueductal gray (PAG), locus coeruleus (LC) and rostral ventromedial-medulla (RVM). PAG is recognised as a major source of pain inhibitory control: its activation produces hypoalgesia by inhibiting nociceptive sensory processing within the dorsal horn of the spinal cord [57, 58]. PAG-induced analgesia is produced through the activation of RVM consisting of the raphe magnus and its adjacent reticular nuclei. Different pain responding cell populations are found in RVM: ON, OFF and neutral cells. These cells show different reactions to nociceptive stimuli such as excitation, inhibition or irresponsiveness, respectively [59, 60]. Apart from their well-documented role in anti-nociception, PAG and RVM mediate also a descending facilitation [61, 62]. Indeed, a shift in the balance between RVM “pronociceptive” ON cells versus “anti-nociceptive” OFF cell activity has been found in neuropathic pain conditions. The ongoing firing of RVM ON cells was found significantly increased whereas the spontaneous activity of the OFF cells appeared decreased 7 days after neuropathic pain induction [60, 63]. A functional shift between ON and OFF cell activity such that ON cell activity predominates over that of the OFF may be responsible of the facilitatory influence of the RVM on spinal neurons leading to neuropathic hypersensitivity [64-66, 16, 67]. Moreover, a contribute of serotonergic neurons, considered a subset of neutral cells, in nociceptive modulation has been evidenced in abnormal pain states [68]. Thus, changes in RVM cell activity may be considered a sort of sensitization of RVM neurons during neuropathic pain [69, 70] as consequence of altered peripheral inputs associated with spinal processing [71]. Alternatively, RVM cell activity changes may reflect a different control exerted from the upstream PAG projections. Indeed, a complex morpho-functional reorganization has been observed within the PAG after neuropathic pain induction. A decrease in the potency of (R)-(+)\{2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrro-
lo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanonemesylate (WIN 55,212-2), a cannabinoid receptor agonist, locally microinjected into the ventrolateral (VL) PAG, has been recently evidenced in neuropathic rats. Seven days after the CCI of the sciatic nerve WIN 55,212-2 produced antinociception and inhibited the activity of the ON cells while increased those one of the OFF cells (as centrally acting analgesic drugs are expected to do) at doses twofold higher than in control rats [67]. Moreover, the expression of cannabinoid type 1 (CB1) receptor, the CB1 receptor associated Goβi3 and the cannabinoid receptor interacting 1a (CRIP 1a) proteins and the endocannabinoid synthesising enzyme NAPE-PLD proved to be decreased in CCI rats [67]. Thus a down regulation of the endocannabinoid system within the VL PAG, possibly due to endocannabinoid increase in neuropathic pain state [72], may lead to an enhancement in pain responses through an altered control of PAG-RVM circuitry on spinal nociceptive neurons. A hyperactivity of serotonergic neurons and an increase in endocannabinoids was also observed in CCI animals in dorsal raphe (DR), an area which lies just ventrally and shows similar morphological properties to the PAG [73]. DR phenotypic changes during neuropathic pain may have also relevance for the affective component of chronic pain. Another supraspinal circuitry being involved in to the emotional-affective aspects of pain is the basolateral amygdala (BLA)-medial prefrontal cortex (mPFC) pathway. Pyramidal neurons of mPFC respond to BLA electrical stimulation or hind-paw pressoceptive stimulation with an inhibitory [BLA→mPFC(-)] or excitatory [BLA→mPFC(+) ] response [74]. These neurons show a phenotypic rearrangement in SNI-induced mono-neuropathy in the rat, suggesting that the mPFC may undergo profound reorganization in chronic pain conditions [75]. Neuraphic pain can shift the balance between excitary and inhibitory responses in the BLA→mPFC pathway, resulting in a net increase in the excitatory influence that the BLA exerts over the prelimbic/infralimbic (PL/IL) neuron population of the mPFC [76-80]. These functional changes appeared concomitantly with an increase in glutamate levels, as well as an up-regulation of fatty acid amide hydrolase (FAAH) enzyme and TRPV1 channels in the PL/IL cortex of SNI rats [75]. Overexpression of several caspases such as caspase-3 and 1, upregulation of glutamate AMPA receptors in microglia, IL-1β and IL-1 receptor-1, TRPV1 and vesicular glutamate transporter 1 (VGluT1) in glutamatergic neurons were also observed 7 days after SNI in mice. Of these alterations, only those in astrocytes persisted in SNI TPRV1(-/-) mice. SNI triggers both TRPV1-dependent and independent glutamate- and caspase-mediated cross-talk among IL-PL cortex neurons and glia, which either participates or counteracts pain processing. Alterations in endovanilloid system associated with peripheral nerve injury may suggest that therapies able to normalize endovanilloid transmission or blocking caspase activation may prove useful in ameliorating symptoms and central sequelae associated with neuropathic pain [80, 75]. Within the VL PAG the expression of pronociceptive mediator targets such as the prostaglandin EP1 receptor, whose activation has pain facilitatory role, proved to be reduced 7 days after neuropathic pain induction by SNI. However, its blockade and stimulation was still able to inhibit/facilitate pain responses and the ON and OFF cell activity, as they did in control animals. The major expression of EP1 receptor was found on GABAergic neurons consistently with an EP1 receptor blockade-induced disinhibition of the antinociceptive descending pathway at VL PAG level and behavioural antinociception [16].
5. Cannabinoids and peripheral neuropathy

The discovery and characterization of cannabinoid receptors (CBRs) in the late eighties [81, 82] and the subsequent isolation of endogenous ligands, first of all the arachidonoylethanola‐mide (AEA) [83], established the existence of a proper endocannabinoid neuromodulatory system. Cannabinoids include the components of the cannabis plant (Cannabis sativa L.), the endogenous cannabinoids (endocannabinoids), and several synthetic cannabinoid ligands. The cannabinoid system is involved in several human physiological functions as testified by the fact that cannabis intake affects important aspects of behaviour such as short-term memory, panic reactions, motor coordination, food-intake and pain perception [84, 85]. More than 70 psychoactive compounds have been identified in cannabis, among which Δ⁹-tetrahydrocannabionol (THC) accounting for most of the psychological and physical effects. Cannabinoids exert their effects through the activation of two G protein-coupled receptors identified as the cannabinoid CB1 and CB2. Their activation is associated with inhibition of adenylate cyclase and the stimulation of mitogen-activated protein kinase (MAPK). Moreover, CB1 receptor activation modulates calcium or potassium conductance properties linked to the reduction of neuronal excitability and neurotransmitter release [86]. CB1 receptor is wide expressed in the brain, including neuroanatomical regions subserving transmission and modulation of pain signals, such as the PAG, the RVM and the dorsal horn of the spinal cord [87, 88]. CB2 is found mainly in the peripheral immune system. It is expressed on T and B cells, macrophages, natural killer and monocytes, however recent studies suggest its expression on neurons at dorsal root ganglia level and at central level within spinal cord, specifically on glia, microglia and neurons [89, 28]. Pharmacological evidence also support the existence of non-CB1/CB2 receptor-mediated cannabinoid effects [90] and different investigations have been identified possible targets in the orphan G protein–coupled receptor GPR55 [91], transient receptor potential vanilloid type-1 (TRPV1) channel [92] or peroxisome proliferator-activated receptors (PPARs) [93]. The endocannabinoids such as AEA, arachidonoylglycerol (2-AG) and N-arachidonoyl-dopamine (NADA) are lipid compounds produced on demand by the cleavage of membrane phospholipid precursors, released from cells immediately after their production and degraded by specific enzymatic system. AEA is synthesized from enzymatic cleavage of N-arachidonoyl phosphatidylethanolamine (NAPE) by a specific phospholipase D (NAPE-PLD). It shows higher affinity for CB (Ki [CB1 vs CB2] = 89 vs 371 nM) and can also activate ionotropic TRPV1 receptors as endovanilloids. Biological inactivation of anandamide occurs through a rapid uptake followed by intracellular hydrolysis mediated by FAAH.

2-AG, which is more abundant than anandamide in the brain binds to CB1 and CB2 with a lower affinity than anandamide, but behaves like a full agonist since it shows higher intrinsic activity [94]. 2-AG is synthesized by the enzyme diacylglycerol lipase (DGL-α) in a Ca²⁺- dependent pathway [95]. Other alternative mechanisms of 2-AG synthesis have also been proposed [96]. Biological inactivation occurs through uptake followed by hydrolysis mediated by the enzyme monoacylglycerol lipase (MGL). Other enzymes have been indicated for 2-AG metabolism, including cyclooxygenases (COXs), lipooxygenases (LOXs) and FAAH [97, 98]. The first evidence of the analgesic properties of cannabis was observed in 1899 by Dixon [99]. Crucial studies on cannabinoid-induced antinociception by Bicher and Mechoulam (1968)
and Kosersky [101] confirmed the ability of cannabinoids to inhibit acute and inflammatory and nerve injury–induced pain. Cannabinoids seem to be useful in alleviating neuropathic pain symptoms after prolonged treatments [102], unlike opioids, which show only limited effectiveness [103, 104]. The activation of the CB receptors by synthetic agonists, or pharmacological elevation of endocannabinoid levels, suppresses hyperalgesia and allodynia in animal models of neuropathic pain. Local administration of exogenous AEA or 2-AG significant decreases the hyperalgesia in formalin test or in the PNL [105, 106]. Systemic FAAH inhibitor (URB597, AA-5-HT, OL-135) administration or the inhibition of endocannabinoid uptake with AM404 produce antinociceptive effects in CCI [107] or PNL models [3] which are mainly CB1 receptor-mediated. It is also important to highlight that inhibitors of FAAH elevate levels of fatty-acid amides that do not bind to CB receptors (e.g. palmitoylethanolamine). Thus, the contribute of non-cannabinoid receptor mechanisms of action in the in vivo pharmacological effects of FAAH and MGL inhibitors must also be considered. Direct evidence for supraspinal sites of cannabinoid analgesic action was derived from the observation that administration of cannabinoids compounds straight into the brain induces antinociception. Martin et al. (1999) [108] demonstrated that WIN55,212-2 produced antinociception in the tail-flick test when injected into different brain regions including subnuclei of the amygdala, thalamus, PAG and RVM.

In addition, as previously briefly described, WIN55,212-2 microinjection into the PAG suppressed the sciatic nerve constriction-induced allodynia and modulated RVM cells activity [67]. Similar effects have been shown by intra-PAG injection of a FAAH inhibitor URB597 which elevates endocannabinoid levels and reduces the thermal nociception via activation of CB1 and TRPV1 receptor mechanisms [109]. Moreover, Giordano et al. (2011) [80] have shown that acute intra-pre-limbic/infra-limbic cortex microinjection of N-arachidonoyl-serotonin (AA-5-HT), a hybrid FAAH inhibitor and TPRV1 channel antagonist, transiently decreased the allodynia and modulates the changes occurring on cortex pyramidal neurons induced by SNI model.

In the complex scenario of neuropathic pain, which also involves non-neuronal pathways, such as microglial cell-induced synaptic plasticity, the endocannabinoid system may also represent target to exploit for modulating microglia-neuron communication. Several studies have focused on CB2 receptor activation in different neuropathic pain models [110, 28, 111, 112].

Such studies have highlighted the role of CB2 receptor in the modulation of immune response involved in the development of neuropathic pain. CB2 receptor activation exerts antiallodynic and antihyperalgesic effects by modulating microglia responses. In particular, CB2 receptor stimulation induced an analgesic effect in SNI mice associated with a reduction in the pro-inflammatory (IFN-γ and IL-1β) and an enhancement in anti-inflammatory (IL-10) mediators within the spinal cord [28]. Beside the analgesic effect, cannabis intake can impair cognitive and performance tasks, such as memory and learning [113]. Activation of central CB1 receptors lead to a combination of stimulatory and depressant effects [114]. Other effects including catalepsy, motor deficits and thermal imbalance have been observed after administration of centrally acting cannabinoids [115]. These effects, mainly associated with activation of central CB1 receptors, deeply limit the clinical use of
cannabinoids for the treatment of chronic pain states. The synthesis of CB2 receptor-selective agonists which lack of the majority of central side effects and produce antinociceptive effects represent an interesting pharmacological tool [116].

Cannabinoids can counteract pain in both physiological and pathological conditions. CB1Rs and CB2Rs are both overexpressed during inflammation and neuropathic pain. In this context, selective activation of peripheral CB1 or CB2 receptor by cannabinoid agents which do not penetrate the blood brain barriers or the enhancement of the endocannabinoid levels can be a promising therapeutic approach that avoid the side effects associated with central CB1 receptor activation. Finally the isolation of non psychotropic compounds of Cannabis Sativa, such as cannabidiol or cannabichromene, which show antinociceptive properties in physiological [117] and pathological [118] pain conditions, could represent an alternative tool in pain management.

6. Stem cell treatment for peripheral neuropathy

Management of peripheral neuropathy in affected patients could be tailored to individual requirements, for instance the presence of other co-morbidities could influence the therapy. Damaged peripheral nerves demonstrate some potential to regenerate, however, complete functional recovery is infrequent. Novel approaches are required in the clinical management of peripheral nerve injuries since the current surgical techniques result in deficient sensory recovery [119].

Nowadays, neuropathy research is focusing on newer cellular and molecular approaches, such as stem cell therapy. Preclinical studies indicate that stem cell therapy represents the great promise for the future of molecular and regenerative medicine, including tissue regeneration. In peripheral neuropathy, stem cells could act in several ways: i) improving the intrinsic regenerative capacity of injured nerves; ii) inhibiting pathogenic immune responses both in the periphery and inside the central nervous system; iii) releasing neuroprotective and anti-inflammatory molecules thus favouring tissue repair.

In the last years, it has been demonstrated that stem cells are neuroprotective in a variety of nervous system injury models [120]. Briefly, stem cells have been found in all multi-cellular organisms, they are able to divide and differentiate into diverse specialized cell types. In addition, stem cells self-renew themselves to produce more stem cells. Indeed, in principle, their extraordinary properties are the self-renewal (the ability to perform indefinite cell division cycles while maintaining the undifferentiated state) and the multipotency (the capacity to differentiate into specialized cell types). The availability of multiple stem cell types provides both the opportunity and a reasoned approach for treating several, otherwise untreatable, human diseases [121].

As neurodegenerative disease, also peripheral neuropathy could benefit by stem cell therapy. This cell-based treatment opportunity represents a non-surgical approaches to enhance nerve recovery and re-innervation processes [122, 123]. Indeed, stem cell implan-
tation appears as a possible curative treatment having the stem cells the ability to incorporate into the site of a lesion, differentiate, and to improve locomotor recovery [124]. Stem cell beneficial effects are due to their properties, as self-renewal ability with the capacity to generate more identical stem cells; the capacity to give rise to more differentiated cells; the capacity to produce neuroprotective and anti-inflammatory molecules (paracrine regulatory functions) [121].

The ideal stem cell source for peripheral neuropathy repair should be easily accessible, involve non-invasive harvesting, be rapidly expandable in *in vitro* culture, be able to survive and integrate within the host nerve tissue [125]. Mesenchymal stem cells (MSCs) represent a promising therapeutic approach in nerve tissue engineering [126]. These cells are a population of progenitor cells of mesodermal origin found in the bone marrow of adults, giving rise to skeletal muscle cells, blood, adipose tissue, vascular and urogenital systems, and to connective tissues throughout the body [127]. This type of stem cells yields most prominent results in peripheral nerve re-generation. In addition, MSCs have great potential as therapeutic agents since they are easy to isolate and can be expanded from patients without serious ethical and technical problems [128]. MSC treatment into a polycaprolactone nerve guide was able to improve re-innervation and activity in mice undergone to nerve transection [129]. Interestingly, some transplanted stem cells assumed a Schwann-cell-like phenotype.

In a murine model of sciatic nerve crush injury, intravenous administration of adipose-derived MSC (ASC) significantly accelerated the functional recovery [126]. Mice showed significant improvement in fiber sprouting and the reduction of inflammatory infiltrates. The authors proposed that ASC-mediated positive effects were due to the production of *in situ* molecules, which, directly or indirectly through a cross-talk with local glia cells, could modulate the local environment with the down-regulation of inflammation and the promotion of axonal regeneration. Peripheral neuropathy is a dramatic symptom in Krabbe disease [130]. Hematopoietic stem cell (HSC) transplantation proved effective in slow the progression of this disease. HSCs were able to achieve improvement in peripheral nerve conduction abnormalities in Krabbe patients, suggesting remyelination of the nerves [131]. Diabetic neuropathy is the most common complication of diabetes, frequently leads to foot ulcers and may progress to limb amputations [132].

It has been proposed that autologous transplantation of bone marrow-derived mononuclear cells (BM-MNCs) could be a novel strategy for the treatment of painful diabetic neuropathy [133]. Indeed, transplantation of BM-MNCs is able to alleviate neuropathic pain in the early stage of streptozotocin-induced diabetic rats. The BM-MNC transplantation significantly ameliorated mechanical hyperalgesia and cold allodynia. Diabetic neuropathy is attracting most research strategies. Several clinical trials have been performed on the use of stem cells for the treatment of human peripheral diabetic neuropathy (www.clinicaltrials.gov). Induced pluripotent stem (iPS) cell technology has enormous potentials to advance medical therapy by personalizing regenerative medicine [134]. iPS cells offer great potentials as a future tool also for the treatment of peripheral neuropathy. Cell incorporation into conduit repair of peripheral nerves demonstrates experimental promise as a novel intervention. Tissue-engineered bio-
absorable nerve conduits coated with iPS cell-derived neurospheres were able to repair peripheral nerve gaps in mice [135].

Achieving peripheral nerve regeneration, axonal regeneration and re-myelination with stem cells is a challenging research goal. This process is very complex, with Wallerian degeneration being the most elementary reaction and Schwann cells playing an important role. An emerging solution to improve upon this intrinsic regenerative capacity is to supplement injured nerves with stem cells [136]. Stem cells effectiveness in the treatment of peripheral nerve injury may lie in their ability to differentiate into Schwann cells, secrete neurotrophic factors, and assist in myelin formation [137, 136]. This strategy of introduction autologous stem cells directly into the site of a nerve injury represents a promising therapy. Skin-derived precursor cells (SKPs) were successfully transplanted in the sciatic nerve of Lewis rats bridged by a freeze-thawed nerve graft.

The cells were able to improve nerve re-generation, probably their effect was due to the ability to secrete bioactive neurotrophins [138]. Another stem cell type, the multipotent hair follicle stem cells, could provide a potential accessible, autologous source of stem cells for regeneration therapy of damaged nerves [139]. More recently, in an interesting study, Amoh et al. transplanted hair follicle stem cells around the impinged sciatic nerve of the mice. The cells differentiated into glia fibrillary acidic protein-positive Schwann cells, promoting the recovery of pre-existing axons. Authors reported that the regenerated sciatic nerve was functionally recovered [140]. These hair follicle stem cells could differentiate into several cell types, i.e. neurons, glia, keratinocytes, smooth muscle cells and melanocytes. They are nestin-positive cells and once implanted into the gap region of the sciatic or tibial nerve, are able to enhance the rate of nerve regeneration and the restoration of nerve function [141]. Wharton’s jelly fish-derived mesenchymal stem cells (WJMSCs) could be also a promising cell source for nerve tissue engineering. It has been demonstrated that these cells can be differentiated into Schwann-like cells and could be suitable Schwann-cell substitutes for nerve repair in clinical applications [142]. A recent strategy for peripheral nerve regeneration is based on the use of CD34(+) cells. Indeed, integration of CD34(+) cells in injured nerve significantly promotes nerve regeneration [143]. However, limited migration and short survival of CD34(+) cells could counteract this beneficial effect. One strategy could be the potentiation of CD34(+) cell recruitment triggered by stromal cell-derived factor-1α (SDF-1α) [143]. This strategy based on the over-expression of SDF-1α is providing interesting results in the peripheral neuropathy treatment. It has been proposed that the expression of SDF-1α in the injured nerve exerts a trophic effect by recruiting progenitor cells that promote nerve regeneration. Intravenous administration of human amniotic fluid-derived mesenchymal stem cells facilitated neural regeneration in a sciatic nerve crush injury model, when recruited by expression of SDF-1α in muscle and nerve after nerve crush injury [144]. As mesenchymal stem cells, amniotic fluid-derived mesenchymal stem cells have the ability to secrete neurotrophic factors that are able to promote neuron survival. Their transplantation was able to regenerate the sciatic nerve after crush injury by secretion of neurotrophic factors [145]. Interestingly, the stem cell mediated effects could be enhanced by co-administration of several anti-inflammatory and anti-
apoptotic factors, i.e. fermented soybean extracts or granulocyte-colony stimulating factor (G-CSF) [146, 147].

In some cases, stem cell therapy does not provide optimal results. The multipotent capacity of stem cells to differentiate into many cell types has led to successful therapy, but concerns remain about the possible negative or harmful effects of the transplanted cultured cells [148]. Mahdi-Rogers et al. treated six patients with chronic acquired demyelinating neuropathy with autologous peripheral blood stem cell transplantation (PBSCT) [149]. These patients were refractory to other treatments; however, the authors reported serious adverse events and lack of sustained response. There have been reports of inflammatory peripheral neuropathy or polyneuropathy associated with chronic graft-versus-host disease (GVHD) [150], even if pathogenesis has not been fully cleared. Doi et al. report a case of immune-mediated neuropathy after allogenic hematopoietic stem cell transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia [151]. On the other hand, a case of peripheral neuropathy induction was reported after autologous blood stem cell transplantation for multiple myeloma [152]. Overall, these data indicate that before being suitable for clinical applications, stem cell biology needs to be investigated further and in greater detail [153].

7. Conclusions

Neuropathic pain involves a complex network of mechanisms involving peripheral and central nervous system. The peripheral nerve injury produces abnormal peripheral afferent inputs at the spinal dorsal horn which leads to development of central sensitization and plastic changes in supraspinal areas. The precise contribute of the different brain sites in neuropathic pain development and maintenance is still far to be established. In particular the contribute of the descending pain modulatory system including the PAG and the RVM is dual varying from inhibitory to facilitatory. By this subject strategies able to shift the balance between facilitatory versus inhibitory influences of the descending pathway may be useful to counteract neuropathic pain symptoms. Cannabinoids have been proved to stimulate the PAG-RVM inhibitory pain control and inhibit neuropathic pain-related allodynia and hyperalgesia.

Neurons are not the only cell type involved in plastic changes at the base of pain hypersensitivity and activated microglia actively contribute to pain facilitation through a tight interaction with neuron activity and the release of pain mediators. Novel strategies based on switching off the microglia activation represents a possible therapeutic intervention to alleviate neuropathic pain.

Human mesenchymal stem cell transplantation has shown to reduce astrocytic and microglial cell activation, mechanical allodynia and cellular and molecular pain mechanisms. The therapeutic potentiality of stem cell to alleviate neuropathic pain appears encouraging, however, its clinical application in peripheral neuropathy requires and deserves further investigations.
Author details
Sabatino Maione, Enza Palazzo, Francesca Guida, Livio Luongo, Dario Siniscalco, Ida Marabese, Francesco Rossi and Vito de Novellis
Department of Experimental Medicine, Division of Pharmacology, Second University of Naples, Naples, Italy

References


[67] Palazzo, E, Luongo, L, Bellini, G, Guida, F, Marabese, I, Boccella, S, Rossi, F, Maione, S, & De Novellis, V. Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-ros-


[76] Fu, Y, & Neugebauer, V. Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in pain-related synaptic facilitation and behavior. J Neurosci. 20089, 28(15), 3861-76.


[91] Sharir, H. and Abood, M.E. Pharmacological characterization of GPR55, a putative cannabinoid receptor Pharmacol. Ther 2010;126(3):301–313


[107] Costa, B, Siniscalco, D, Trovato, A. E, Comelli, F, Sotgiu, M. L, Colleoni, M, Maione, S, Rossi, F, & Giagnoni, G. AM404, an inhibitor of anandamide uptake, prevents pain


